ITeos Therapeutics

ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.

movers image

FTEL

ITOS

MUFG

SEDG

SKYH

VSAT

Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday&#39;s Pre-Market Session

Crude Oil 6- logo

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ASND

NCNA

NUVL

Crude Oil Surges Over 1%; Instil Bio Shares Plunge

Movers

Pre-Market Outlook

HYLN

MRNO

MSTR

NVMI

SLDB

UPST

VZLA

iTeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday&#39;s Pre-Market Session

ITeos Therapeutics Inc

Earnings

Press Releases

iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates

Health Care

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024

iTeos to Participate in Upcoming Investor Conferences

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Economics

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

Anika Therapeutics

Annexon

aTyr Pharma

Benitec Biopharma

Cidara Therapeutics

Celcuity

Cardiff Oncology

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Design Therapeutics

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharma

Foghorn Therapeutics

Gossamer Bio

Immutep Limited - American Depositary Shares

Immutep

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Neurogene

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Prime Medicine

Regenxbio

Rezolute

Tourmaline Bio

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Verastem

XOMA Royalty

Y-mAbs Therapeutics

HC Wainwright & Co.

Wells Fargo

JP Morgan

Wedbush

Comments

ITeos Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga